Metamizol is indicated for the management of acute, severe pain that does not respond adequately to other non-opioid options. This may include pain experienced following surgical procedures (postoperative pain), pain related to trauma, or the spasmodic discomfort of colic. The medication is also a therapeutic option for the temporary reduction of high fever (pyrexia) when other conventional measures are insufficient or inappropriate.

A key benefit is its use in addressing pain of visceral origin, such as that associated with renal or biliary colic. In these scenarios, Metamizol’s properties may aid in relieving the acute, sharp sensations and supporting patient comfort during these episodes. The overall goal is effective symptomatic relief across these specific acute domains.

Quick Fact: Relief for Severe Pain

Regulatory References

1. EMA therapeutic overview

Who Can and Cannot Use Metamizol?

Metamizol's eligibility profile is strictly defined by regulatory documents, listing absolute prohibitions and conditional restrictions.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

• Patients with a history of agranulocytosis induced by Metamizol or chemically related pyrazolone/pyrazolidine medicines.
• Patients with impaired bone marrow function or established diseases of the hematopoietic system.
• Patients with known analgesic-induced asthma syndrome or other severe analgesic intolerance.
• Women in the third trimester of pregnancy.
• Infants below the age of 3 months or those under 5 kg of body weight.

---

Conditional and Restricted Use

Use is subject to limitations or dose adjustments for specific groups:

• Organ Impairment: Dose reduction is necessary for patients with established hepatic impairment or renal impairment, and multiple high doses must be avoided.
• Pregnancy/Lactation: Use during the first six months of pregnancy is restricted to cases where other analgesics are unsuitable. Breastfeeding requires discarding milk for a 48-hour period after a single dose.
• Age: Adults and adolescents ge 15 years are the standard population. Children's doses are weight-based, and fixed-dose forms are not recommended for younger children.

Interactions with other medicines and products

Metamizol's interaction profile is officially defined by its capacity to modify the plasma concentrations of certain co-administered medicines, primarily through pharmacokinetic mechanisms, and by documented pharmacodynamic interference.

Documented Interaction Patterns

Type of Interaction	Description of Official Regulatory Statement
Exposure-Modifying	Metamizol is a moderate to strong inducer of the metabolic enzymes CYP3A4, CYP2B6, and CYP2C19. This effect reduces the plasma concentrations (exposure) of substrates like Ciclosporin, Bupropion, Methadone, Quetiapine, and Valproic acid.
Pharmacodynamic	Metamizol inhibits the antiplatelet effect of low-dose Acetylsalicylic Acid (ASA) used for cardiovascular risk reduction.
Toxicity Risk	The combination with Methotrexate carries a mandatory warning regarding an increased risk of severe haematologic toxicity (e.g., myelosuppression). Co-administration with Chlorpromazine may lead to additive hypothermia.

Regulatory Constraints

For low-dose Acetylsalicylic Acid (ASA), official regulatory documents require separation in administration timing to mitigate the inhibition of the antiplatelet effect. The severe haematologic toxicity risk with Methotrexate functions as a high-level restriction against co-administration documented in product information.

Metamizol, following metabolism to active components, exerts its effects primarily through engagement within the Central Nervous System (CNS) and peripheral tissues. Its mechanism involves multiple distinct pathways to modulate physiological responses.

---

Central Prostaglandin Synthesis Inhibition

Metamizol acts within domains involving enzyme-mediated signaling by inhibiting the synthesis of prostaglandins (specifically PGE2) in the CNS, likely through a preference for a variant of the cyclooxygenase enzyme, COX-3. This modification of an early molecular step decreases the excitability of nociceptors and maintains modulation within pathways involving thermal and noxious stimuli transmission.

---

Endogenous Opioidergic and Cannabinoid System Modulation

Metamizol affects systems where specific transmitters or mediators dominate, such as the endogenous opioidergic and cannabinoid systems. This interaction is thought to activate descending inhibitory pathways in the brain that influence the transmission of heightened physiological signals.

---

Smooth Muscle Spasmolysis

In peripheral tissues, Metamizol modulates pathways associated with heightened smooth muscle contraction. This involves mechanisms that lead to the reduced release of intracellular Ca^2+, which directly influences the regulation of processes driven by distinct signaling patterns in muscle tissue, resulting in reduced Ca^2+ mobilization and subsequent relaxation of smooth muscle tone.

Administration Routes and Standard Dosing

Metamizol is officially administered through multiple approved routes, including oral forms (tablets, drops), rectal forms (suppositories), and parenteral forms (intravenous or intramuscular injection solution). For adults and adolescents over 15 years, the standard single oral or parenteral dose ranges from 500 mg to 1,000 mg (1 g). The maximum permitted daily dose is 4,000 mg (4 g). Dosing may be repeated up to four times daily, provided a minimum interval of six to eight hours is consistently maintained between administrations, as outlined in official labeling. The drug is generally intended for short-term use.

---

Procedural and Population-Specific Requirements

Oral forms can be taken without reference to meals, accompanied by a glass of water. Intravenous administration requires specific procedural constraints: the injection must be administered very slowly, typically over a period of 5 to 10 minutes, and the patient should remain in a recumbent position during the procedure. The injection solution may require dilution with standard IV fluids prior to use. Dosage for pediatric patients is calculated based on body weight. For older adults or patients with existing hepatic or renal impairment, it is necessary to consider dose reduction or avoidance of high multiple doses. If a dose is missed, patients should take the next dose at the regularly scheduled time.

Evidence for Acute, Severe Pain and Postoperative Pain

This section summarizes the evidence derived from short-term, randomized controlled trials (RCTs) and systematic reviews focusing on changes in pain intensity over short periods, particularly in adults after surgery or following an acute injury. These studies were designed to monitor changes in pain intensity scores—a measure of outcomes related to physical discomfort—and to track the subsequent use of additional pain-relieving medication. The findings describe patterns observed in the study populations, particularly a rapid change in measured pain intensity in the immediate hours following administration compared to a placebo. However, the evidence is limited because research is often based on single-dose study designs focused on the immediate onset and duration of action. Long-term effects are not fully established.

---

Evidence for Acute Visceral Pain (Colic)

This part reviews research that evaluated Metamizol in the context of specific types of spasmodic pain, such as renal or biliary colic. The clinical trials explored short-term symptom changes and focused on outcomes describing episodic or acute changes, measuring the rapid change of acute pain intensity. Studies report how symptoms evolved in the observed populations, noting changes in pain intensity measurements within the first hour of treatment. The number of large-scale RCTs focusing solely on colic pain is limited. Evidence quality varies across studies, and certainty remains low regarding comparisons across all available research for these conditions.

---

Evidence for High Fever (Pyrexia) and Special Populations

Research has explored using Metamizol for outcomes related to systemic or functional imbalance, specifically concerning the reduction of elevated body temperature. Studies monitored changes in body temperature at specific intervals. The research highlights measurable changes in body temperature over the short-term monitoring period (e.g., within 24 hours). Research has also explored the use of the medicine in children (pediatric populations) and older adults.

The evidence for use in children can be heterogeneous, and data for certain groups remain insufficient. Similarly, dedicated research focusing specifically on how age and comorbid conditions were evaluated in outcomes remains limited. Follow-up durations were limited in the highest-quality acute pain trials, meaning that long-term outcomes remain an area that is not yet fully characterized.

Key Studies & References

1. Metamizole-containing medicinal products (EMA Article 31 referral, CHMP opinion on dosing, pregnancy, and breastfeeding, 2018)

Common questions about Metamizol (FAQ)

---

Q: Does Metamizol cause drowsiness or make you feel sleepy?

A: Official safety documents indicate that drowsiness (somnolence) and dizziness are possible side effects of Metamizol. Because of this potential for temporary impairment, regulatory documents note that caution may be necessary regarding activities that require attention, such as driving or operating machinery, due to these potential effects.

---

Q: Can Metamizol interact with medications taken for chronic conditions like diabetes or high cholesterol?

A: Yes, official product information warns that Metamizol is a known enzyme inducer. This means it can speed up the way the body processes many other medications, such as those used for chronic conditions. This effect may reduce the plasma concentrations and thus the overall effectiveness of co-administered drugs. Information about potential interactions underscores the importance of patient-specific assessment regarding co-administered medications.

---

Q: What official sources say about taking Metamizol with alcohol?

A: Regulatory documents and patient information generally note that use with alcohol is advised against or requires caution. This caution is based on the potential for increased risk of certain adverse reactions, resulting from the combination of the two substances.

---

Q: Do regulatory bodies advise specific monitoring when taking Metamizol?

A: Regulatory documents advise patients to stop treatment immediately and seek urgent medical attention if certain symptoms appear (such as fever, sore throat, or painful mouth/throat changes). These symptoms are listed as potential indicators of agranulocytosis, a rare but serious side effect. General guidance notes that routine blood monitoring is not detailed as a required measure for all users.

---

Q: Does Metamizol have anti-inflammatory properties?

A: Metamizol is officially classified primarily as a powerful analgesic (pain reliever) and antipyretic (fever reducer). While some regulatory and scientific summaries state that it has weak or minor anti-inflammatory properties, this is not described as its main therapeutic role. Official therapeutic indications primarily list the treatment of acute severe pain (e.g., after surgery or due to colic) and high fever.

---

Q: Is Metamizol ever used to treat migraine headaches?

A: Official therapeutic indications primarily list the treatment of acute severe pain and high fever. While the medicine may be used for various types of pain, migraine headaches are generally not listed as an approved indication in core regulatory summaries.

---

Q: Is Metamizol commonly used in veterinary medicine, and does this affect its human use perception?

A: Metamizol is officially approved and used in veterinary medicine in some jurisdictions. However, regulatory actions and safety profile assessments for the human drug are based primarily on human safety data and are treated separately from its veterinary use.

---

Q: Does Metamizol contain gluten or lactose?

A: The inclusion of excipients like lactose or gluten is product-specific and depends entirely on the formulation (e.g., tablet or injection solution) of the specific medicine a person receives. A comprehensive list of these inactive ingredients is listed in the excipients section of the drug's approved patient information leaflet or SmPC.

---

Q: Does the time of day a person takes Metamizol matter, according to instructions?

A: Official instructions emphasize the critical importance of maintaining the required minimum interval of 6 to 8 hours between doses to prevent overuse. However, regulatory documents do not specify a mandatory time of day for administration; adherence to the spacing interval is the key requirement.

---

Q: Are there any warnings about driving or operating machinery while taking Metamizol?

A: Yes, regulatory documents include warnings regarding activities that require full focus. Due to the potential for side effects such as dizziness or somnolence (drowsiness), caution is advised, as the ability to drive or operate machinery may be impaired.

---

Q: Does Metamizol affect the stomach in the same way that NSAIDs do?

A: Regulatory information and supporting scientific evidence often note that Metamizol is associated with less gastrointestinal toxicity compared to classical non-steroidal anti-inflammatory drugs (NSAIDs). Its mechanism of action appears to result in a different profile of effects on the stomach and digestive system.

How to Store and Dispose of Metamizol

Metamizol must be stored according to regulatory labeling to maintain its stability. The medication, such as the injection solution, must be kept below 25°C and should not be stored in the freezer. The product must be protected from degradation by storing it in the original package to shield it from light. Like all medicines, Metamizol must be kept out of the sight and reach of children.

Disposal of unused or expired Metamizol requires following official regulatory procedures. The preferred method is returning the medicine to a drug take-back program. If this option is unavailable, the product may be discarded in the household trash by mixing it with an undesirable substance, sealing it in a container, and then disposing of it.